Objective Antibiotics resistance of pathogens is a major threat to public health and safety. The rapid spread of resistant strains increases the risk of epidemics. This issue also includes preparedness to deal with bio-terrorism. The objectives of the ET-PA project are to develop an open, generic platform to enable the development of new classes of protein-antibiotics. The key technology (REPPs) is based on a principle that is proprietary to one of the participating SMEs, consisting of rationally modified class II restriction enzymes (RE) fused to cell penetration peptide sequences (PP) that selectively allow microbial cell penetration. Introduction of a REPP system into pathogens would lead to effective cell killing. The REPP will be designed to inactivate major microbial pathogens, i.e. S. aureus, P. aeruginosa and C. Albicans. Addressing these ambitious objectives will require a Co-operative Research setup with complementing expertise and resources, coming both from high-tech SMEs and expert academic RTD partners. The ET-PA project will be divided into four work packages:1.Discovery -The design of a technology platform for the discovery of PP sequences for proper function in antibiotic REPP constructs.2.Characterization -extensive characterization of the biological activity of antibiotic REPP constructs.3.Technological platform - configuration of a semi-automatic and embedding technology platform that enables a coherent and unified approach for a rapid translation of REPP components into protein antibiotics.4.Management - to assure, consolidation and coordination of the ET-PA project, support and protection of Intellectual Property, and contacts to subsequently license the outcomes to a third-party end-user.The commitment and collective efforts of all participants is the best warranty for a success of the ET-PA project that will provide a technology platform to translate the most effective horizontal bacterial defence system into innovative medicine. Fields of science medical and health scienceshealth sciencespublic healthnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomicsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistancenatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes Programme(s) FP6-SME - Horizontal research activities involving SMEs: Specific activities covering wider field of research under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) SME-1 - Co-operative Research (all areas of science and technology) Call for proposal FP6-2003-SME-1 See other projects for this call Funding Scheme Data not available Coordinator ADRIACELL SRL. EU contribution No data Address S.S.14km163.5 TRIESTE Italy See on map Links Website Opens in new window Total cost No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all BIA SEPARATIONS D.O.O. Slovenia EU contribution No data Address Teslova 30 LJUBLJANA See on map Links Website Opens in new window Total cost No data HECUS X-RAY SYSTEMS GMBH Austria EU contribution No data Address Moserhofgasse 15 GRAZ See on map Links Website Opens in new window Total cost No data RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN Germany EU contribution No data Address Sigmund-Freud-Strasse 25 BONN See on map Links Website Opens in new window Total cost No data UNIVERSITA DEGLI STUDI DI TRIESTE. Italy EU contribution No data Address Piazzale Europa 1 TRIESTE See on map Links Website Opens in new window Total cost No data